Literature DB >> 12131545

Muscular side effects of statins.

Helmut Sinzinger1, Roswitha Wolfram, Bernhard A Peskar.   

Abstract

Lipid lowering has been shown to be effective in preventing primary and recurrent cardiovascular events and to save life. Statins almost exclusively used for this purpose meanwhile became one of the most widely prescribed families of drugs world-wide. Myopathies--mainly not well characterized--are the major group of side effects. We here review different types of clinical appearances, localizations, symptoms and the biochemical background. The data indicate that severe muscular side effects are rare. Patients and their doctors, however, easily overlook mild ones. Myopathic symptoms without any known biochemical correlate are not rare. No general guideline exists about exact diagnosis and differential diagnosis. Strict adherence to the measures of life-style change and performance of regular exercise can even further enhance significantly these side effects. Much more research should be directed onto the pathophysiological (genetic?) background to finally evaluate possible therapeutic consequences rather than simply to withdraw or change the respective statin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12131545     DOI: 10.1097/00005344-200208000-00001

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  24 in total

1.  Statin-associated muscle-related adverse effects: a case series of 354 patients.

Authors:  Stephanie Cham; Marcella A Evans; Julie O Denenberg; Beatrice A Golomb
Journal:  Pharmacotherapy       Date:  2010-06       Impact factor: 4.705

Review 2.  Statins and CVD prevention in the diabetic population: implications of the CARDS trial.

Authors:  Omar Murad; John Palmer; James Sowers; Samy I McFarlane
Journal:  Curr Diab Rep       Date:  2005-06       Impact factor: 4.810

3.  Statin myopathy: incidence, risk factors, and pathophysiology.

Authors:  Kimberly A Sewright; Priscilla M Clarkson; Paul D Thompson
Journal:  Curr Atheroscler Rep       Date:  2007-11       Impact factor: 5.113

4.  Mitophagy protects against statin-mediated skeletal muscle toxicity.

Authors:  Mridula Ramesh; Juliane C Campos; Pamela Lee; Yang Song; Genaro Hernandez; Jon Sin; Kyle C Tucker; Hannaneh Saadaeijahromi; Michael Gurney; Julio C B Ferreira; Allen M Andres
Journal:  FASEB J       Date:  2019-08-23       Impact factor: 5.191

Review 5.  Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis.

Authors:  Eva Dolezelova; Evan Stein; Giuseppe Derosa; Pamela Maffioli; Petr Nachtigal; Amirhossein Sahebkar
Journal:  Br J Clin Pharmacol       Date:  2017-03-10       Impact factor: 4.335

6.  A randomized clinical trial to assess the effect of statins on skeletal muscle function and performance: rationale and study design.

Authors:  Paul D Thompson; Beth A Parker; Priscilla M Clarkson; Linda S Pescatello; C Michael White; Adam S Grimaldi; Benjamin D Levine; Ronald G Haller; Eric P Hoffman
Journal:  Prev Cardiol       Date:  2010

7.  Statin therapy and the expression of genes that regulate calcium homeostasis and membrane repair in skeletal muscle.

Authors:  Annette Draeger; Verónica Sanchez-Freire; Katia Monastyrskaya; Hans Hoppeler; Matthias Mueller; Fabio Breil; Markus G Mohaupt; Eduard B Babiychuk
Journal:  Am J Pathol       Date:  2010-05-20       Impact factor: 4.307

8.  The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity.

Authors:  Jun-ichi Hanai; Peirang Cao; Preeti Tanksale; Shintaro Imamura; Eriko Koshimizu; Jinghui Zhao; Shuji Kishi; Michiaki Yamashita; Paul S Phillips; Vikas P Sukhatme; Stewart H Lecker
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

9.  Oxidation injury in patients receiving HMG-CoA reductase inhibitors: occurrence in patients without enzyme elevation or myopathy.

Authors:  Helmut Sinzinger; Fahdi Chehne; Graziana Lupattelli
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

10.  Simvastatin impairs exercise training adaptations.

Authors:  Catherine R Mikus; Leryn J Boyle; Sarah J Borengasser; Douglas J Oberlin; Scott P Naples; Justin Fletcher; Grace M Meers; Meghan Ruebel; M Harold Laughlin; Kevin C Dellsperger; Paul J Fadel; John P Thyfault
Journal:  J Am Coll Cardiol       Date:  2013-04-10       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.